COMFINTE vs INDOUS: Stock Comparison
COMFINTE is the larger company by market capitalisation. COMFINTE shows a higher dividend yield, faster revenue growth and lower leverage, while INDO US BIOTECH shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
COMFINTE leads 5; INDOUS leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | COMFINTE | INDOUS |
|---|---|---|
| Sector | — | Fast Moving Consumer Goods |
| Industry | — | Other Agricultural Products |
Price
| Metric | COMFINTE | INDOUS |
|---|---|---|
| Live Price | ₹9.17 | ₹65.34 |
| Day Change | -9.92% | -1.85% |
| Volume | 2.21 Cr | 4,878 |
| 52-Week High | ₹11.19 | ₹159 |
| 52-Week Low | ₹5.21 | ₹57.5 |
| Distance from 52W High | -18.05% | -58.91% |
Valuation
| Metric | COMFINTE | INDOUS |
|---|---|---|
| Market Cap | ₹200 Cr | ₹134 Cr |
| P/E Ratio | 0x | 0x |
| P/B Ratio | 1.13x | 0x |
| EPS | ₹-0.06 | ₹1,69,098.66 |
| Book Value | ₹5.73 | ₹63.54 |
| Dividend Yield | 0.8% | 0% |
Growth
| Metric | COMFINTE | INDOUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -22% |
| EPS Growth (TTM YoY) | 0% | -47.3% |
| Qtr Sales Growth | 1.24% | 0% |
| Qtr Profit Growth | -144.72% | 0% |
Profitability & Leverage
| Metric | COMFINTE | INDOUS |
|---|---|---|
| ROE | -1.6% | 14.18% |
| ROCE | 1.58% | 10.86% |
| Net Margin | -1.67% | 11.88% |
| Operating Margin | 3.1% | 14.64% |
| Debt to Equity | 0.18x | 0.4x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | COMFINTE | INDOUS |
|---|---|---|
| Promoter Holding | 56.13%▲ 0.05 pp | 68.29% |
| FII Holding | 0% | 0.01% |
| DII Holding | 0% | 0.25%▲ 0.25 pp |
| Public Holding | 43.87%▼ 0.05 pp | 31.45%▼ 0.25 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: COMFINTE and INDO US BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.